What the trial actually tested
For decades, patients with small-cell lung cancer (SCLC) who responded to initial chemotherapy or chemoradiation were routinely offered prophylactic cranial irradiation (PCI) — a preventive course of whole-brain radiation given even when scans showed no cancer in the brain. The rationale dated to the pre-MRI era, when studies showed PCI reduced brain metastases and improved survival. But that evidence predated the accuracy of modern MRI, and PCI carries known cognitive risks.
The phase 3 SWOG S1827 trial, known as MAVERICK, was designed to settle the question with a randomized comparison rather than retrospective data. Across 139 institutions in six countries, researchers enrolled 304 patients with limited- or extensive-stage SCLC who had no brain metastases on a baseline scan (about 68% limited-stage, 32% extensive-stage). Patients were randomized to brain MRI surveillance alone, or to the same MRI surveillance schedule plus PCI (25 Gy in 10 fractions, mostly with hippocampal avoidance). Results were presented by Dr. Chad Rusthoven of the University of Colorado School of Medicine at the 2026 World Conference on Lung Cancer (WCLC) in Seoul, as covered by Radiology Business.
The primary endpoint was cognitive failure-free survival — time until cognitive decline or death. MRI surveillance alone cut that risk by 40% relative to MRI plus PCI (hazard ratio 0.60, 90% CI 0.46-0.78, p=0.001), according to results reported by Medical Xpress. At six months, cognitive failure-free survival was 37.8% in the MRI-alone arm versus 16.5% in the combined arm.
The survival trade-off — and what's still pending
Skipping radiation only makes sense if it doesn't cost patients survival time or let brain metastases go undetected. On both counts, the preliminary data held up, according to Medical Xpress. Overall survival, analyzed at 128 of a planned 190 deaths, showed no significant difference between arms (hazard ratio 0.90, 90% CI 0.67-1.20) — final analysis is still pending. Brain metastasis-free survival also did not differ significantly between groups (hazard ratio 1.25, 90% CI 0.95-1.66).
Meanwhile, serious treatment-related side effects were far less common without radiation: grade 3 or higher adverse events occurred in 0.8% of the MRI-alone group versus 7.9% of the combined group (p=0.004), including one fatal case of radiation-related encephalopathy in the PCI arm. Dr. Rusthoven summarized the takeaway plainly in the trial's press release: the results "support MRI surveillance alone as the standard of care for patients with SCLC."
The imaging math underneath the headline
The clinical story is about cognition and quality of life. The operational story, for radiology, is about what "MRI surveillance" actually requires. In MAVERICK, the surveillance schedule was brain MRI (with matched cognitive testing) every three months in year one and every six months in year two — six contrast-enhanced brain scans over two years per patient. Radiation, by contrast, is a single course delivered once.
If this trial's results move guidelines — and a randomized phase 3 readout at a major international conference is exactly the kind of evidence that does — a treatment decision that used to be a single upfront radiation course becomes a multi-year imaging commitment. The American Cancer Society estimates roughly 229,410 new lung cancer diagnoses in the US for 2026, and small-cell tumors account for an estimated 10-15% of those cases. Most SCLC patients present without brain metastases at diagnosis, which is the population this schedule would apply to. Applied at scale, a schedule of six brain MRIs over two years for even a fraction of newly diagnosed SCLC patients nationally adds a durable, recurring line item to brain MRI volume — not a one-time bump, but a multi-year obligation that renews with each new diagnosis, layered on top of scans already being read for lung, staging, and unrelated indications.
That is the pattern worth naming: guideline changes rarely announce themselves as capacity problems. A trial result framed around cognitive outcomes and radiation toxicity is also, quietly, a decision about how many brain MRIs a radiology department will read over the next several years for a disease that hasn't gotten any more common.
Same pattern, different specialty
This isn't an isolated case. Every time a professional society tightens or loosens an eligibility threshold, or a randomized trial like MAVERICK replaces a one-time intervention with a recurring imaging protocol, the volume implication lands on radiology — not on the specialty that changed the guideline. The table below distinguishes MAVERICK's brain-MRI surveillance shift from two related but separate volume drivers already covered on this blog.
| Driver | What changed | Volume effect |
|---|---|---|
| Brain-met surveillance (this article) | PCI replaced by MRI surveillance in SCLC | Recurring brain MRIs per patient, multi-year, replacing a one-time treatment |
| Screening-criteria expansion | Simpler lung-cancer screening eligibility rules | More people newly eligible for annual low-dose chest CT |
| General overutilization | Fewer utilization-management gatekeepers | Broad increase in imaging orders across modalities |
Each driver adds volume for a different reason — new patients, new eligibility, or fewer checks. MAVERICK is the narrowest and most traceable of the three: a fixed patient population, a defined scan schedule, and a specific hazard ratio behind the decision. See how screening-criteria changes add CT volume and the broader capacity-squeeze picture for the other two.
Where xAID fits
None of this changes how a brain MRI should be read — it changes how many will need to be read, on a schedule, for years, by departments that aren't adding radiologists at the same rate. That's the throughput problem AI CT and MRI reporting is built to absorb: the system produces a structured, ready-to-sign draft report, xAID's in-house radiologist reviews every preliminary, and the reading radiologist signs off before it reaches a patient's chart. A recurring surveillance protocol is exactly the kind of predictable, high-volume workload where draft-then-sign reporting compounds — the same report structure, run six times over two years, for a growing number of patients.
Frequently asked questions
What did the MAVERICK trial find about brain MRI vs. preventive brain radiation?
The phase 3 SWOG S1827 (MAVERICK) trial randomized 304 small-cell lung cancer patients with no brain metastases at baseline to brain MRI surveillance alone or to MRI surveillance plus prophylactic cranial irradiation (PCI). MRI surveillance alone improved the trial's primary endpoint, cognitive failure-free survival, by 40% (hazard ratio 0.60, 90% CI 0.46-0.78, p=0.001), with no significant difference in preliminary overall survival or brain metastasis-free survival, and far fewer serious treatment-related side effects.
How often do patients get brain MRIs under the surveillance protocol?
In the MAVERICK trial, both arms received brain MRI (and matched cognitive testing) every 3 months during year one and every 6 months during year two — six scans over two years per patient. If MRI-alone surveillance replaces prophylactic cranial irradiation as the standard approach, that repeating schedule becomes the norm for a patient population that previously might have received a single course of preventive radiation instead.
Why does this matter for radiology departments, not just oncology?
Small-cell lung cancer accounts for roughly 10-15% of the estimated 229,410 new lung cancer cases projected in the US for 2026, and most present without brain metastases at diagnosis. A guideline shift toward MRI surveillance converts a one-time radiation course into a recurring, contrast-enhanced brain MRI obligation for that population — a concrete, traceable example of how a single evidence-based practice change adds recurring imaging volume onto radiology departments, distinct from screening-eligibility expansions or general overutilization trends.
Is prophylactic cranial irradiation still recommended for small-cell lung cancer?
PCI has been standard practice for decades based on pre-MRI-era evidence. MAVERICK is the first randomized phase 3 trial to test it head-to-head against modern MRI surveillance and its results, presented at the 2026 World Conference on Lung Cancer, support MRI surveillance alone as the preferred approach — but final overall survival results are still pending (128 of a planned 190 deaths analyzed at this readout), so guideline bodies have not yet formally updated their recommendations.
Source: Radiology Business, reporting on the phase 3 SWOG S1827 (MAVERICK) trial presented at the 2026 World Conference on Lung Cancer, with additional results detail from Medical Xpress, the trial's press release, and the International Lung Cancer News (ILCN/WCLC) conference coverage. Lung cancer incidence figures from the American Cancer Society. Figures are rounded as reported; overall survival results were preliminary at the time of presentation.